KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$9.9 million.

  • Neogenomics' Profit After Tax rose 3551.94% to -$9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$108.0 million, marking a year-over-year decrease of 3721.64%. This contributed to the annual value of -$108.0 million for FY2025, which is 3721.64% down from last year.
  • According to the latest figures from Q4 2025, Neogenomics' Profit After Tax is -$9.9 million, which was up 3551.94% from -$27.1 million recorded in Q3 2025.
  • Neogenomics' Profit After Tax's 5-year high stood at $75.9 million during Q2 2021, with a 5-year trough of -$49.4 million in Q1 2022.
  • For the 5-year period, Neogenomics' Profit After Tax averaged around -$21.4 million, with its median value being -$23.5 million (2022).
  • Data for Neogenomics' Profit After Tax shows a peak YoY increase of 121185.52% (in 2021) and a maximum YoY decrease of 89577.63% (in 2021) over the last 5 years.
  • Neogenomics' Profit After Tax (Quarter) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then skyrocketed by 35.52% to -$9.9 million in 2025.
  • Its Profit After Tax stands at -$9.9 million for Q4 2025, versus -$27.1 million for Q3 2025 and -$45.1 million for Q2 2025.